<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>RYANODEX Â DANTROLENE SODIUM
- dantrolene sodiumÂ injection, suspensionÂ </strong><br>Eagle Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use RYANODEX safely and effectively. See full prescribing information for RYANODEX. <br>RYANODEX<span class="Sup">Â®</span> (dantrolene sodium) for injectable suspension, for intravenous use. <br>Initial U.S. Approval: 1974
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">RYANODEX is a skeletal muscle relaxant drug indicated for:
 </p>
<ul class="Disc">
<li>Treatment of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> in conjunction with appropriate supportive measures. (<a href="#s1">1</a>)
</li>
<li>Prevention of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> in patients at high risk. (<a href="#s1">1</a>)
</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>
<span class="Underline">Treatment of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">Malignant Hyperthermia</span> (MH)</span> (<a href="#s3">2.1</a>)<ul class="Disc">
<li>Administer by intravenous push at a minimum of 1 mg/kg. If signs continue, administer additional intravenous boluses up to maximum cumulative dosage of 10 mg/kg.
</li>
<li>Institute supportive measures (e.g., discontinue MH-triggering agents, manage <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, cooling if necessary, administer diuretics)
</li>
</ul>
</li>
<li>
<span class="Underline">Prevention of MH in Patients at High Risk</span> (<a href="#s4">2.2</a>)<ul class="Disc">
<li>Administer 2.5 mg/kg intravenously over a period of at least 1 minute, starting approximately 75 minutes prior to surgery.
</li>
<li>Avoid agents that trigger MH.
</li>
<li>Administer additional individualized doses during anesthesia and surgery if surgery is prolonged.
</li>
</ul>
</li>
<li>
<span class="Underline">Pediatric Patients</span>:   recommended weight-based dose is the same as for adults (<a href="#s5">2.3</a>)
</li>
<li>
<span class="Underline">Reconstitution</span>:  With 5 mL of sterile water for injection (without a bacteriostatic agent) prior to administration (<a href="#s6">2.4</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">For injectable suspension:  250 mg of lyophilized powder in a single-use vial for reconstitution (<a href="#s7">3</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None (<a href="#s8">4</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Underline">Skeletal <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span></span>:  Ambulate patients with assistance until they have normal strength and balance (<a href="#s10">5.1</a>)
</li>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>, respiratory <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, and decreased <span class="product-label-link" type="condition" conceptid="4105475" conceptname="Inspiratory capacity">inspiratory capacity</span></span>:  Monitor patients for the adequacy of ventilation (<a href="#s10">5.1</a>)
</li>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">Dysphasia</span></span>: Assess patients for difficulty swallowing and <span class="product-label-link" type="condition" conceptid="4096712" conceptname="Choking">choking</span> (<a href="#s10">5.1</a>)
</li>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></span>:  Can occur following RYANODEX administration; may persist up to 48-hours post-dose. Ambulate patients with assistance until they have normal strength and balance.(<a href="#s11">5.2</a>)
</li>
<li>
<span class="Underline">Tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">Necrosis</span> with <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span></span>: Due to high pH of reconstituted RYANODEX for injectable suspension, care must be taken to prevent <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> into surrounding tissues (<a href="#s12">5.3</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disc">
<li>Administration to conscious subjects is associated with loss of grip strength and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in the legs, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.
</li>
<li>Other common adverse reactions are: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> secondary to <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, and <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span> (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>) (<a href="#s14">6.1</a>)
</li>
</ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Eagle at <br>1-855-318-2170 or FDA at 1-800-FDA-1088 or
</span><span class="Bold Italics">www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Underline">Calcium channel blockers</span>: Concomitant use can cause <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span> in association with marked <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (<a href="#s21">7.1</a>)
</li>
<li>
<span class="Underline">Muscle relaxants</span>: Concomitant use with muscle relaxants may potentiate their effects (<a href="#s22">7.2</a>)
</li>
<li>
<span class="Underline">Sedatives</span>: Concomitant use with sedative agents may potentiate their effects (<a href="#s23">7.3</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Underline">Pregnancy</span>: Based on animal data, may cause fetal harm (<a href="#s25">8.1</a>)
</li>
<li>
<span class="Underline">Nursing Mothers</span>: Discontinue drug or nursing (<a href="#s28">8.3</a>)
</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 7/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE
</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosage for Treatment of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">Malignant Hyperthermia</span>
</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosage for Prevention of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">Malignant Hyperthermia</span>
</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dosage for Pediatric Patients
</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Reconstitution and Administration Instructions
</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle Weakness</span>
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Potential for Tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">Necrosis</span> with <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span>
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience
</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience
</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Calcium Channel Blockers
</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Muscle Relaxants
</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Antipsychotics and Antianxiety Agents
</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery
</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use
</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE
</a></h1>
<h2><a href="#section-9.1" class="toc">10.1 Overdosage Symptoms
</a></h2>
<h2><a href="#section-9.2" class="toc">10.2 Management of Overdosage
</a></h2>
<h1><a href="#section-10" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics
</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics
</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-13" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-14" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE
</h1>
<p class="First">RYANODEX<span class="Sup">Â®</span> is indicated for the:
</p>
<ul class="Disc">
<li>Treatment of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> in conjunction with appropriate supportive measures <span class="Italics">[see Dosage and Administration (<a href="#s3">2.1</a>)]</span>
</li>
<li>Prevention of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> in patients at high risk.
</li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosage for Treatment of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">Malignant Hyperthermia</span>
</h2>
<p class="First">In addition to RYANODEX treatment, institute the following supportive measures:
</p>
<ul class="Disc">
<li>Discontinue use of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> (MH)-triggering anesthetic agents (i.e., volatile anesthetic gases and succinylcholine).
</li>
<li>Manage the <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>
</li>
<li>Institute cooling when necessary
</li>
<li>Administer diuretics to prevent late kidney injury due to <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span> (the amount of mannitol in RYANODEX is insufficient to maintain <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>) <span class="Italics">[see Description (<a href="#s34">11</a>)]</span>
</li>
</ul>
<p>Administer RYANODEX by intravenous push at a minimum dose of 1 mg/kg.  If the physiologic and metabolic abnormalities of MH continue, administer additional intravenous boluses up to the maximum cumulative dosage of 10 mg/kg.
</p>
<p>If the physiologic and metabolic abnormalities reappear, repeat RYANODEX dosing by intravenous push starting with 1 mg/kg.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dosage for Prevention of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">Malignant Hyperthermia</span>
</h2>
<p class="First">The recommended <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> dose of RYANODEX is 2.5 mg/kg administered intravenously over a period of at least 1 minute, starting approximately 75 minutes prior to surgery.  Avoid agents that trigger MH.
</p>
<p>If surgery is prolonged, administer additional individualized RYANODEX doses during anesthesia and surgery <span class="Italics">[see Clinical Pharmacology (<a href="#s38">12.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Dosage for Pediatric Patients
</h2>
<p class="First">The recommended weight-based dose of RYANODEX for pediatric patients in the treatment and prevention of MH is the same as for adults for these indications <span class="Italics">[see Dosage and Administration (<a href="#s3">2.1</a>, <a href="#s4">2.2</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Reconstitution and Administration Instructions
</h2>
<p class="First">The supplied lyophilized powder must be reconstituted prior to administration:
</p>
<ol class="LittleAlpha">
<li>Reconstitute each vial of RYANODEX lyophilized powder by adding 5 mL of sterile water for injection (without a bacteriostatic agent). Do not reconstitute with any other solution (e.g., 5% dextrose injection, 0.9% sodium chloride injection).
</li>
<li>Shake the vial to ensure an orange-colored uniform suspension. Visually inspect the vial for particulate matter and discoloration prior to administration.
</li>
<li>Must use the contents of the vial within 6 hours after reconstitution. Store reconstituted suspensions at controlled room temperature (68Â°F to 77Â°F or 20Â°C to 25Â°C).
</li>
</ol>
<p>Do not dilute or transfer the reconstituted RYANODEX suspension to another container to infuse the product.
</p>
<p>Administer the reconstituted RYANODEX suspension either:
</p>
<ul class="Disc">
<li>Into the intravenous catheter while an intravenous infusion of 0.9% sodium chloride injection, or 5% dextrose injection is freely running; or
</li>
<li>Into the indwelling catheter - after assuring its patency - without a freely running infusion.  Flush the line to assure that there is no residual RYANODEX remaining in the catheter <span class="Italics">[see Warnings and Precautions (<a href="#s12">5.3</a>)].</span>
</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s7"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">For injectable suspension:  RYANODEX is a sterile, lyophilized powder containing 250 mg of dantrolene sodium for reconstitution, in single use vials
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s8"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS
</h1>
<p class="First">None
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s9"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle Weakness</span>
</h2>
<p class="First">RYANODEX is associated with skeletal <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>.  The administration of RYANODEX in human volunteers has been associated with loss of grip strength and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in the legs.  Patients should not be permitted to ambulate without assistance until they have normal strength and balance.
</p>
<p>RYANODEX has been associated with <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, respiratory <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, and decreased <span class="product-label-link" type="condition" conceptid="4105475" conceptname="Inspiratory capacity">inspiratory capacity</span>.  Monitor patients for the adequacy of ventilation.
</p>
<p>RYANODEX has been associated with <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">dysphasia</span>.  Assess patients for difficulty swallowing and <span class="product-label-link" type="condition" conceptid="4096712" conceptname="Choking">choking</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> can occur following administration of RYANODEX and may persist up to 48-hours post-dose.  Patients should not be permitted to ambulate without assistance until they have normal strength and balance.  Patients must not operate an automobile or engage in other hazardous activities for 48-hours post-dose.
</p>
<p>The concomitant use of sedative agents with RYANODEX may increase the risk of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Potential for Tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">Necrosis</span> with <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span>
</h2>
<p class="First">Care must be taken to prevent <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> of RYANODEX into the surrounding tissues due to the high pH of the reconstituted RYANODEX suspension and potential for tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s13"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience
</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
</p>
<p>In a study designed to evaluate the safety and tolerability of RYANODEX, healthy volunteers were randomly assigned to receive treatment with RYANODEX or an active comparator at doses ranging from 1 mg/kg to 2.5 mg/kg.
</p>
<ul class="Disc">
<li>The RYANODEX dose was infused over the course of 1 minute for each of the doses evaluated.
</li>
<li>The active comparator was an injectable formulation of dantrolene sodium that differed from RYANODEX in that it contained dantrolene sodium and mannitol at concentrations of 0.33 mg/mL and 50 mg/mL, respectively, when reconstituted according to the product's prescribing information.  The active comparator was infused at a rate that administered 20 mg of dantrolene per minute for each of the doses evaluated.
</li>
</ul>
<p><a href="#t1">Table 1</a> displays the most common adverse events in this study.  These data are not an adequate basis for comparison of the types or frequencies of adverse event types between RYANODEX and the dantrolene sodium comparator.
</p>
<p>Adverse events increased in frequency with increasing doses in the trial, but did not differ in frequency between the two treatment groups. RYANODEX-treated subjects were more likely to report immediate adverse events of <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, and <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span> than those receiving the active comparator.
</p>
<p>In all dose groups, hand grip strength declined after dosing. In general, the decline in hand grip strength was more pronounced and occurred more rapidly in the RYANODEX-treated subjects in the 1.0, 1.75, 2.0 and 2.25 mg/kg treatment groups. In the 2.5 mg/kg treatment group, the decline in hand grip strength both in amount and duration was similar between the two treatment groups.
</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1: Adverse Events in Healthy Volunteers
</span></caption>
<col align="left" width="43.867%">
<col align="left" width="24.367%">
<col align="left" width="31.767%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="middle"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="middle"><span class="Bold">Number(%) of subjects</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">RYANODEX</span><br><span class="Bold">[N=30]</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">Dantrolene Sodium Comparator</span><br><span class="Bold">[N=31]</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">8 (27)
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 (3)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">5 (17)
</td>
<td class="Botrule Rrule" align="center" valign="middle">4 (13)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">Dysphonia</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">4 (13)
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 (3)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">3 (10)
</td>
<td class="Botrule Rrule" align="center" valign="middle">4 (13)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">3 (10)
</td>
<td class="Botrule Rrule" align="center" valign="middle">3 (10)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4075224" conceptname="Feeling bad">Feeling abnormal</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">3 (10)
</td>
<td class="Botrule Rrule" align="center" valign="middle">3 (10)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 (3)
</td>
<td class="Botrule Rrule" align="center" valign="middle">4 (13)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 (3)
</td>
<td class="Botrule Rrule" align="center" valign="middle">2 (6)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision blurred</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 (3)
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 (3)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 (3)
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 (3)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscular Weakness</span>/<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 (3)
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 (3)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">Atrioventricular block</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 (3)
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 (3)
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â Infusion site <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 (3)
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">1 (3)
</td>
<td class="Botrule Rrule" align="center" valign="middle">0
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience
</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of another formulation of dantrolene sodium for injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-6.2.1"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary Edema</span></span></p>
<p>There have been reports of <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> developing during the treatment of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> crises with another dantrolene sodium dosage form.  The contributory effect of the diluent volume and mannitol in these cases is not known.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-6.2.2"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span> and Tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">Necrosis</span></span></p>
<p>There have been reports of <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> following administration of intravenous dantrolene. Tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> secondary to <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> has been reported <span class="Italics">[see Warnings and Precautions (<a href="#s12">5.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-6.2.3"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span></span></p>
<p>There have been reports of <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> possibly associated with the administration of dantrolene sodium for injection. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> has been reported.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-6.2.4"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection Site Reactions</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reactions</span> including <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, commonly due to <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>, have been reported.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s20"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Calcium Channel Blockers
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">Cardiovascular collapse</span> in association with marked <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> has been reported in patients receiving dantrolene in combination with calcium channel blockers. The concomitant use of RYANODEX and calcium channel blockers is not recommended during the treatment of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Muscle Relaxants
</h2>
<p class="First">The concomitant administration of RYANODEX with muscle relaxants may potentiate the neuromuscular block.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Antipsychotics and Antianxiety Agents
</h2>
<p class="First">The concomitant administration of RYANODEX with antipsychotic and antianxiety agents may potentiate their effects on the central nervous system <span class="Italics">[see Warnings and Precautions (<a href="#s11">5.2</a>)]</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s24"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s25"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Underline">Pregnancy Category C</span></p>
<p>Adequate and well controlled studies have not been conducted with RYANODEX in pregnant women.  However, animal reproduction studies have been conducted with dantrolene sodium.  In these studies, dantrolene sodium administered to rats and rabbits produced embryolethality (rabbits) and decreased pup survival (rats) at doses seven times the human oral dose.   RYANODEX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s27"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery
</h2>
<p class="First">In one uncontrolled study, 100 mg per day of <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> oral dantrolene sodium was administered to term pregnant patients awaiting labor and delivery. Dantrolene readily crossed the placenta, with maternal and fetal whole blood levels approximately equal at delivery; neonatal levels then fell approximately 50% per day for 2 days before declining sharply. No neonatal respiratory and neuromuscular side effects were observed in this study.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s28"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First">Dantrolene is present in human milk.  In one case report, low dantrolene concentrations (less than 2 micrograms per milliliter) were measured in the breast milk of a lactating woman during repeat intravenous dantrolene administration over 3 days. Because of the potential for serious adverse reactions of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in nursing infants from dantrolene, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s29"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First">The safety and efficacy of RYANODEX in the treatment and prevention of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> in pediatric patients is based on clinical experience with other intravenous dantrolene sodium products, which suggests adult weight-based doses are appropriate for pediatric patients.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s30"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First">Clinical studies of RYANODEX did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s31"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-9.1"></a><p></p>
<h2>10.1 Overdosage Symptoms
</h2>
<p class="First">Overdosage symptoms include, but are not limited to, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span> and alterations in the state of consciousness (e.g., <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-9.2"></a><p></p>
<h2>10.2 Management of Overdosage
</h2>
<p class="First">Employ general supportive measures for acute overdosage of RYANODEX.
</p>
<p>Administer intravenous fluids in fairly large quantities to avert the possibility of <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>. Maintain an adequate airway and keep artificial resuscitation equipment available. Institute electrocardiographic monitoring and carefully observe the patient. The value of dialysis in RYANODEX overdosage is not known.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s34"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First">RYANODEX<span class="Sup">Â®</span> (dantrolene sodium) for injectable suspension is a sterile lyophilized powder. RYANODEX is supplied in 20 mL vials containing 250 mg dantrolene sodium and the following inactive ingredients: 125 mg mannitol, 25 mg polysorbate 80, 4 mg povidone K12 and sufficient sodium hydroxide or hydrochloric acid for pH adjustment.  When reconstituted with 5 mL sterile water for injection USP (without a bacteriostatic agent), this yields a suspension with a pH of approximately 10.3.
</p>
<p>RYANODEX is a skeletal muscle relaxant. Chemically, RYANODEX is a hydrate of 1-[[[5-(4-nitrophenyl)-2-furanyl]methylene]amino]-2,4-imidazolidinedione sodium salt. The structural formula for the hydrated salt is:
</p>
<p><a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8f7b3ac0-604d-4c78-b545-5e0f8ea3d698&amp;name=dan00-0001-01.jpg"></p>
<p>The hydrated salt contains approximately 15% water (3-1/2 moles) and has a molecular weight of 399. The anhydrous salt (dantrolene) has a molecular weight of 336.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s35"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s36"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First">In isolated nerve-muscle preparation, dantrolene has been shown to produce relaxation by affecting the contractile response of the muscle at a site beyond the myoneural junction. In skeletal muscle, dantrolene dissociates the excitation-contraction coupling, probably by interfering with the release of Ca<span class="Sup">++</span> from the sarcoplasmic reticulum.
</p>
<p>In the anesthetic-induced <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> syndrome, evidence points to an intrinsic abnormality of skeletal muscle tissue. In affected humans, it has been postulated that â€œtriggering agentsâ€? (e.g., general anesthetics and depolarizing neuromuscular blocking agents) produce a change within the cell which results in an elevated myoplasmic calcium. This elevated myoplasmic calcium activates acute cellular catabolic processes that cascade to the <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> crisis.
</p>
<p>The addition of dantrolene to the â€œtriggeredâ€? malignant hyperthermic muscle cell may reestablish a normal level of <span class="product-label-link" type="condition" conceptid="4125860" conceptname="Calcium electrolyte">ionized calcium</span> in the myoplasm. Inhibition of calcium release from the sarcoplasmic reticulum by dantrolene reestablishes the myoplasmic calcium equilibrium, increasing the percentage of bound calcium. In this way, physiologic, metabolic, and biochemical changes associated with the <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> crisis may be reversed or attenuated.
</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s37"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics
</h2>
<p class="First">The administration of intravenous dantrolene to human volunteers was associated with loss of grip strength and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in the legs, as well as subjective CNS complaints <span class="Italics">[see Warnings and Precautions (<a href="#s10">5.1</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s38"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics
</h2>
<p class="First">The pharmacokinetics of RYANODEX was investigated in healthy volunteers following single-dose administration as an intravenous push over 60 seconds (dose range of 1 to 2.5 mg/kg), via a peripheral catheter.  There was a dose-proportional increase in plasma exposure of dantrolene and its metabolite, 5-hydroxydantrolene.  <a href="#t2">Table 2</a> presents pharmacokinetic parameters of dantrolene after administration of single RYANODEX dose of 2.5 mg/kg.  Time to peak dantrolene concentration was observed at the first time point collected (i.e. median T<span class="Sub">max</span> is 1 minute post-dose).  The mean half-life (t<span class="Sub">1/2</span>) for dantrolene was independent of the RYANODEX dose administered and ranged from 8.5 hours to 11.4 hours over the 1 to 2.5 mg/kg dose range.
</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2:  Pharmacokinetic Parameters for Dantrolene in Healthy Volunteers (Mean Â± Standard Deviation)
</span></caption>
<col align="left" width="15.150%">
<col align="left" width="15.283%">
<col align="left" width="16.650%">
<col align="left" width="14.667%">
<col align="left" width="15.667%">
<col align="left" width="22.583%">
<tfoot><tr class="First Last"><td align="left" colspan="6" valign="top"><p class="First Footnote"><span class="Sup">1</span> n=15; single dose
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">RYANODEX dose<span class="Sup">1</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">C<span class="Sub">max</span><br>(Î¼g/mL)
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">AUC<span class="Sub">0-inf</span><br>(Î¼g*h/mL)
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">Half-life (hrs)
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">Clearance<br>(L/hr)
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">Volume of distribution (L)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle">2.5 mg/kg
</td>
<td class="Botrule Rrule" align="center" valign="middle">9.0 Â± 4.6
</td>
<td class="Botrule Rrule" align="center" valign="middle">77.7 Â± 23.2
</td>
<td class="Botrule Rrule" align="center" valign="middle">10.8 Â± 2.2
</td>
<td class="Botrule Rrule" align="center" valign="middle">2.5 Â± 1.0
</td>
<td class="Botrule Rrule" align="center" valign="middle">36.4 Â± 11.7
</td>
</tr>
</tbody>
</table>
<p>When <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> intravenous dantrolene infusion was administered, whole blood dantrolene concentrations remained at a near steady state level for 3 or more hours after the infusion was completed.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Underline">Distribution</span></p>
<p>Based on assays of whole blood and plasma, slightly greater amounts of dantrolene are associated with red blood cells than with the plasma fraction of blood. Significant amounts of dantrolene are bound to plasma proteins, mostly albumin, and this binding is readily reversible.  Binding to plasma protein is not significantly altered by diazepam, diphenylhydantoin, or phenylbutazone. Binding to plasma proteins is reduced by warfarin and clofibrate and increased by tolbutamide.
</p>
<p>Information concerning the passage of dantrolene across the blood-brain barrier is not available.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Underline">Metabolism</span></p>
<p>Dantrolene is found in measurable amounts in blood and urine. Its major metabolites in body fluids are 5-hydroxy dantrolene and an acetylamino metabolite of dantrolene. Another metabolite with an unknown structure appears related to the latter. Dantrolene may also undergo hydrolysis and subsequent oxidation forming nitrophenylfuroic acid.  Following RYANODEX 2.5 mg/kg dose administration in healthy volunteers, mean  peak plasma concentration for the primary metabolite, 5-hydroxydantrolene, was 640 ng/mL, and was achieved by approximately 24 hours post-dose, with an average metabolite-to-parent exposure ratio of 0.27 (AUC<span class="Sub">0-inf</span> = 21.2 Î¼g*h/mL). Median t<span class="Sub">1/2</span> for 5-hydroxydantrolene was 10 hours, the clearance was estimated to be 8.9 L/hr and the terminal phase volume of distribution was 144Â L.
</p>
<p>Dantrolene is metabolized by the liver, and it is possible that its metabolism may be enhanced by drugs known to induce hepatic microsomal enzymes. However, neither phenobarbital nor diazepam appears to affect dantrolene metabolism.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s41"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s42"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-12.1.1"></a><p></p>
<p class="First"><span class="Underline">Carcinogenesis</span></p>
<p>Sprague-Dawley female rats fed dantrolene sodium for 18 months at dosage levels of 15, 30, and 60 mg/kg/day showed an increased incidence of benign and malignant mammary tumors compared with concurrent controls. At the highest dose level (approximately the same as the maximum recommended daily human dose on a mg/m<span class="Sup">2</span> basis), there was an increase in the incidence of benign hepatic lymphatic neoplasms. In a 30-month study in Sprague- Dawley rats fed dantrolene sodium, the highest dose level (approximately the same as the maximum recommended daily human dose on a mg/m<span class="Sup">2</span> basis) produced a decrease in the time of onset of mammary neoplasms. Female rats at the highest dose level showed an increased incidence of hepatic lymphangiomas and hepatic angiosarcomas.
</p>
<p>The only drug-related effect seen in a 30-month study in Fischer-344 rats was a dose-related reduction in the time of onset of mammary and testicular tumors. A 24-month study in HaM/ICR mice revealed no evidence of carcinogenic activity.
</p>
<p>The significance of carcinogenicity data relative to use of RYANODEX in humans is unknown.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-12.1.2"></a><p></p>
<p class="First"><span class="Underline">Mutagenesis</span></p>
<p>Dantrolene sodium has produced positive results in the Ames <span class="Italics">S. Typhimurium</span> bacterial mutagenesis assay in the presence and absence of a liver activating system.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-12.1.3"></a><p></p>
<p class="First"><span class="Underline">Impairment of Fertility</span></p>
<p>Dantrolene sodium administered to male and female rats at dose levels up to 45 mg/kg/day (approximately 1.4 times the maximum recommended daily human dose on a mg/m<span class="Sup">2</span> basis) showed no adverse effects on fertility or general reproductive performance.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s46"></a><a name="section-13"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First">RYANODEX<span class="Sup">Â®</span> (NDC 42367-540-32) is available in 20 mL vials containing a sterile lyophilized mixture of 250 mg dantrolene sodium for reconstitution with 5 mL sterile water for injection USP (without a bacteriostatic agent) to yield an orange colored injectable suspension.
</p>
<p>Store unreconstituted product at 20 Â°C to 25 Â°C (68 ÂºF to 77 ÂºF) [see USP Controlled Room Temperature], with excursions permitted to 15 ÂºC to 30 ÂºC (59 ÂºF to 86 ÂºF) and avoid prolonged exposure to light.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s47"></a><a name="section-14"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<p class="First">Inform patients, their families, or their caregivers of the following:
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s48"></a><a name="section-14.1"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle Weakness</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle weakness</span> (i.e. decrease in grip strength and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> of leg muscles, especially walking down stairs) is likely to occur with the use of RYANODEX.  Patients should be provided assistance with standing and walking until their strength has returned to normal <span class="Italics">[see Warnings and Precautions (<a href="#s10">5.1</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s49"></a><a name="section-14.2"></a><p></p>
<p class="First"><span class="Underline">Difficulty Swallowing</span></p>
<p>Caution is indicated at meals on the day of administration because difficulty swallowing and <span class="product-label-link" type="condition" conceptid="4096712" conceptname="Choking">choking</span> have occurred with the use of dantrolene sodium products in general; <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span> has been reported with the use of RYANODEX <span class="Italics">[see Warnings and Precautions (<a href="#s10">5.1</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s50"></a><a name="section-14.3"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></span></p>
<p>The use of RYANODEX has been associated with <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.  <span class="Italics">[see Warnings and Precautions (<a href="#s11">5.2</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-14.4"></a><p></p>
<p class="First"><span class="Underline">Driving or Operating Machinery</span></p>
<p>Symptoms such as â€œlightheadednessâ€? may occur. Since some of these symptoms may persist for up to 48 hours, patients must not operate an automobile or engage in other hazardous activity during this time <span class="Italics">[see Warnings and Precautions (<a href="#s11">5.2</a>)]</span>.
</p>
<p>Marketed by:<br>Eagle Pharmaceuticals, Inc.<br>Woodcliff Lake, NJ 07677
</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s52"></a><a name="section-15"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel - Carton Label</span></p>
<p><span class="Bold">NDC 42367-540-32 Single Use Only -</span></p>
<p><span class="Bold">Sterile   Discard Unused Portion</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold Italics">Ryanodex</span><span class="Bold Italics"><span class="Sup">Â®</span></span></p>
<p>(dantrolene sodium)<br>for injectable suspension
</p>
<p><span class="Bold">250 mg per vial</span></p>
<p><span class="Bold">Reconstitution yields 50 mg/mL</span></p>
<p><span class="Bold">For treatment of malignant<br><span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, along with the<br>appropriate supportive measures.</span></p>
<p><span class="Bold">For intravenous use only</span></p>
<p><span class="Bold">Reconstitute with Sterile Water for Injection, USP</span></p>
<p><span class="Bold">SEE PACKAGE INSERT FOR COMPLETE<br>PREPARATION INSTRUCTIONS AND<br>PRESCRIBING INFORMATION.</span></p>
<div class="Figure">
<a name="f02"></a><img alt="Principal Display Panel - Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8f7b3ac0-604d-4c78-b545-5e0f8ea3d698&amp;name=dan00-0001-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s53"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel - Vial Label</span></p>
<p><span class="Bold">NDC 42367-540-32 Single Use Only -</span></p>
<p><span class="Bold">Sterile   Discard Unused Portion</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold Italics">Ryanodex</span><span class="Bold Italics"><span class="Sup">Â®</span></span></p>
<p>(dantrolene sodium)<br>for injectable suspension
</p>
<p><span class="Bold">250 mg per vial</span></p>
<p>Reconstitution yields 50 mg/mL
</p>
<p>For treatment of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>,<br>along with the appropriate supportive measures.
</p>
<p><span class="Bold">For Intravenous Use Only</span></p>
<p><span class="Bold">Reconstitute with Sterile Water for Injection, USP</span></p>
<div class="Figure">
<a name="f03"></a><img alt="Principal Display Panel - Vial Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8f7b3ac0-604d-4c78-b545-5e0f8ea3d698&amp;name=dan00-0001-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RYANODEX Â 		
					DANTROLENE SODIUM
</strong><br><span class="contentTableReg">dantrolene sodium injection, suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42367-540</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>dantrolene sodium</strong> (dantrolene) </td>
<td class="formItem">dantrolene sodium</td>
<td class="formItem">250Â mg Â inÂ 5Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>povidone k12</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Polysorbate 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>nitrogen</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42367-540-32</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA205579</td>
<td class="formItem">07/23/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Eagle Pharmaceuticals, Inc.
							(849818161)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">AAI Pharma Services Corp.</td>
<td class="formItem"></td>
<td class="formItem">832394733</td>
<td class="formItem">MANUFACTURE(42367-540)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6ca95e99-3bf4-43c7-bb67-1a1d87edf158</div>
<div>Set id: 8f7b3ac0-604d-4c78-b545-5e0f8ea3d698</div>
<div>Version: 2</div>
<div>Effective Time: 20140801</div>
</div>
</div>Â <div class="DistributorName">Eagle Pharmaceuticals, Inc.</div></p>
</body></html>
